News
Stay up to date with CellCentric and follow us on Twitter
Key information, updates and news can be found through our tweets
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. https://lnkd.in/dCQqFTag
Endpoints coverage: https://lnkd.in/dZUP6TbU
Tomasz and Kris in Madrid for #EHA2024. CellCentric’s novel oral drug, inobrodib, in Phase II trials for multiple myeloma.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. https://lnkd.in/dCQqFTag
Endpoints coverage: https://lnkd.in/dZUP6TbU
Tomasz and Kris in Madrid for #EHA2024. CellCentric’s novel oral drug, inobrodib, in Phase II trials for multiple myeloma.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Beyond and alongside antibody-based therapies for multiple myeloma, there is a need for novel oral agents, that can be taken in the community.
Great to have Laura Stoppel, RA Capital, join our board, alongside Irena Melnikova of Pfizer Ventures. Exciting times as we press on with developing inobrodib!
Fabulous to see inobrodib, our pioneering oral p300/CBP inhibitor drug, maintain full momentum towards registration studies. See: https://www.cellcentric.com/press-release/cellcentric-secures-35-million-investment-from-ra-capital-management/
Delighted to confirm $35m from RA Capital Mgmt, plus support from the American Cancer Society’s BrightEdge. https://lnkd.in/dCQqFTag
Endpoints coverage: https://lnkd.in/dZUP6TbU
Tomasz and Kris in Madrid for #EHA2024. CellCentric’s novel oral drug, inobrodib, in Phase II trials for multiple myeloma.
Healthcare systems face a double issue: declining numbers of oncology experts and a lack of hospital space. See post: https://www.linkedin.com/feed/update/urn:li:activity:7196442598700449792/
Latest press releases
